国际眼科纵览 ›› 2026, Vol. 50 ›› Issue (4): 253-259.doi: 10.3760/cma.j.cn115500-20260326-26403

• 综述 • 上一篇    下一篇

铁死亡在青光眼发病机制与治疗中的作用

吴仁毅1, 2, 3  周咏薇3  郑檀3   

  1. 1 厦门大学附属厦门眼科中心 福建省眼表与角膜病重点实验室 眼表与角膜疾病重点实验室 厦门市眼部疾病临床医学研究中心厦门市眼部疾病重点实验室,福建厦门 361001;2 宁波鄞州眼科医院,浙江宁波 315199;3 上海大学附属上海和平眼科医院,上海 200437
  • 收稿日期:2026-03-26 出版日期:2026-08-25 发布日期:2026-08-14
  • 通讯作者: 吴仁毅,Email:wubasel@hotmail.com
  • 基金资助:
    厦门市自然科学基金(3502Z202374133);福建省自然科学基金(2024J011320);华厦科研基金(HXKY202301D004、HXKY202306A003)

The role of ferroptosis in the pathogenesis and treatment of glaucoma

Wu Renyi1,2, 3, Zhou Yongwei3, Zheng Tan3   

  1. 1  Institute and Affiliated Xiamen Eye Center of Xiamen University, Fujian Provincial Key Laboratory of Corneal & Ocular Surface Diseases, Municipal Key Laboratory of Corneal & Ocular Surface Diseases, Xiamen Research Center for Eye Diseases and Key Laboratory of Ophthalmology, Xiamen Fujian 361001, China; 2 Ningbo Yinzhou Eye Hospital, Ningbo Zhejiang 315199, China; 3 Shanghai Peace Eye Hospital,  Shanghai University, Shanghai 200437, China
  • Received:2026-03-26 Online:2026-08-25 Published:2026-08-14
  • Contact: Wu Renyi, Email: wubasel@hotmail.com
  • Supported by:
    Natural Science Foundation of Xiamen, China (3502Z202374133); Natural Science Foundation of Fujian Province (2024J011320); Huaxia Scientific Research Foundation (HXKY202301D004, HXKY202306A003)

摘要: 青光眼是一种以视神经损伤和视野缺损为特征的眼病,近年来的研究揭示了铁死亡在青光眼的发病机制中可能发挥的重要作用。铁死亡作为一种铁依赖性的脂质过氧化驱动的调节性细胞死亡形式,被证实广泛参与青光眼的发病过程。本文综述了铁死亡在青光眼发生发展中的分子机制与研究进展。铁死亡通过铁代谢紊乱、脂质过氧化蓄积及GPX4等关键分子调控异常,诱导视网膜神经节细胞死亡与小梁网细胞功能障碍。在青光眼动物模型及临床样本中,均观察到铁死亡相关标志物的显著变化。针对铁死亡关键节点(如GPX4、ACSL4、NCOA4等)的干预策略,包括铁螯合剂、小分子抑制剂及基因治疗,在临床前模型中展现出明确的神经保护与降眼压效果。铁死亡与氧化应激、兴奋性毒性及神经炎症等病理过程相互交织,共同推动青光眼进展。靶向铁死亡为青光眼治疗提供了超越单纯降眼压的新策略,具有重要的临床转化潜力。然而,目前证据主要来自动物模型和体外实验,铁死亡是疾病驱动因素还是继发性结果仍有待明确;从系统生物学视角整合多条信号通路,将有助于更全面理解其机制。

关键词: 青光眼, 神经保护, 铁死亡

Abstract: Glaucoma is an ophthalmic disease characterized by optic nerve damage and visual field defects. Recent studies have revealed that ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is extensively involved in the pathogenesis of glaucoma. This article provides a systematic review of the molecular mechanisms and research progress on ferroptosis in the development and progression of glaucoma. Ferroptosis induces retinal ganglion cell death and trabecular meshwork dysfunction through iron metabolism dysregulation, accumulation of lipid peroxides, and aberrant regulation of key molecules such as GPX4. Significant alterations in ferroptosis-related markers have been observed in both animal models of glaucoma and clinical samples. Intervention strategies targeting key nodes of ferroptosis (e.g., GPX4, ACSL4, NCOA4), including iron chelators, small-molecule inhibitors, and gene therapy, have demonstrated clear neuroprotective and intraocular pressure-lowering effects in preclinical models. Ferroptosis intertwines with other pathological processes such as oxidative stress, excitotoxicity, and neuroinflammation, collectively driving glaucoma progression. Targeting ferroptosis offers a novel strategy for glaucoma treatment that extends beyond simple intraocular pressure reduction and holds significant potential for clinical translation.However, current evidence is mainly derived from animal models and in vitro experiments, and whether ferroptosis is a driver or a consequence of glaucoma remains to be clarified. A systems biology perspective integrating multiple signaling pathways may facilitate a more comprehensive understanding of the disease mechanisms.

Key words: Glaucoma, Neuroprotection, Ferroptosis